Table 4.
Observed antiviral activity (EC50) against SARS‐CoV‐2 and cytotoxicity (CC50) of the six compounds evaluated using the Caco‐2 cell assay
| Compounda | EC50 visual CPE (µM) | CC50 (µM) |
|---|---|---|
| Remdesivir (positive control) | 1.3 | >100 |
| Itraconazole | 1.6 | >100 |
| Nelfinavir | 8.1 | 6.7 |
| Doxorubicin | 12 | >100 |
| RG‐12915 | 12 | >25 |
| Sematilide | >100 | >100 |
Abbreviations: CC50, cytotoxic concentration of the compound that reduced cell viability to 50%; CPE, cytopathic effect; EC50, concentration of the compound that inhibited 50% of the virus‐induced CPE; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
a
Hydroxychloroquine and chloroquine were not tested in this cell line.